ArTara Therapeutics (id:6973 TARA)
2.39 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 12:27:40 AM)
Exchange closed, opens in 1 day 9 hours
3.02 USD (3.02%)
-1.04 USD (-1.04%)
33.52 USD (33.52%)
-14.95 USD (-14.95%)
99.17 USD (99.17%)
-80.22 USD (-80.22%)
-99.43 USD (-99.43%)
-99.47 USD (-99.47%)
About ArTara Therapeutics
Market Capitalization 53.22M
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
| Headquarters (address) |
345 Park Avenue South New York 10010 NY United States |
| Phone | 646 844 0337 |
| Website | https://www.protaratx.com |
| Employees | 26 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | TARA |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.20 - 5.24 |
| Market Capitalization | 53.22M |
| P/E trailing | -0.669 |
| P/E forward | -0.806 |
| Price/Book | 0.578 |
| Beta | 1.79 |
| EPS | -3.03 |
| EPS United States (ID:6, base:3403) | 24.22 |